Tag: Lung cancer
US FDA Approves Trastuzumab Deruxtecan for the treatment of HER2-Mutant NSCLC
The United States Food and Drug Administration (FDA) has approved trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with...
Combinations with Datopotamab Deruxtecan Show Promising Clinical activity in Treatment of...
Initial results from the TROPION-Lung02 Phase Ib trial demonstrated that that datopotamab deruxtecan (Dato-DXd), a specifically designed TROP2-directed DXd antibody drug conjugate (ADC) being...
Patritumab Deruxtecan Shows Tumor Response Across Multiple Resistance Mechanisms in Patients...
New data presented at this year’s annual meeting of the American Society of Clinical Oncology, held online June 4 - 8, 2021, confirms promising...
AbbVie Discontinues Research and Development Program for Rovalpituzumab Tesirine
MERU, a Phase III trial evaluating rovalpituzumab tesirine (Rova-T / SC16LD6.5; AbbVie) as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated...
WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and...
The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung cancer (NSCLC) accounts for 80%–90%...
Preliminary Phase I Data for U3-1402 Shows Manageable Safety and Reduction...
Preliminary results from the dose escalation part of the phase I study with U3-1402, an investigational and potential first-in-class HER3 targeting antibody-drug conjugate or...
Phase I Data for SAR408701 Supports Further Development in Lung Cancer
During the upcoming annual meeting American Society of Clinical Oncology (ASCO) in June 2019, Sanofi's oncology franchise will present a renewed strategy to address...
Researchers Find SCLC-biopsy Specimen Reliable for Evaluating DLL3 Expression
High levels of delta-like protein 3 or DLL3 in small-cell lung cancer or SCLC are correlated with poor survival trends. Li-Xu Yan, MD, a...
Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...
Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...
Mersana’s XMT-1536 Demonstrates Anti-tumor Activity in Lung Cancer Patient-Derived Xenograft Studies
Encouraging data from preclinical studies presented at the 2016 IASLC 17th World Conference on Lung Cancer, in Vienna, Austria, suggests that Mersana Therapeutics' immunoconjugate XMT-1536...
